Skip to main content

Table 4 Prognostic ability of individual HPV detection methods

From: Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population

Group

p16

ISH

GP5+/6+ PCR

All cases (n = 138)

0.24 (0.15-0.39)

0.27 (0.16-0.46)

0.29 (0.18-0.47)

All cases excluding equivocals (n = 128)

0.22* (0.13-0.37)

0.25 (0.14-0.43)

0.26 (0.16-0.44)

HMBS positive cases (n = 83)

0.20 (0.10-0.37)

0.33 (0.18-0.62)

0.22 (0.12-0.41)

HMBS positive cases excluding equivocals (n = 78)

0.20* (0.10-0.38)

0.27 (0.14-0.53)

0.20 (0.10-0.38)

  1. Hazard ratios (HR) for overall survival, with 95% confidence intervals, are shown for each HPV testing method.
  2. * When ‘equivocal’ cases (with discrepant p16 and HPV DNA testing results) are excluded, analyses for p16 and the composite criterion for HPV positivity based on 3 markers are equivalent and represent the ‘gold standard’.